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Abstract 
 
Resveratrol is a polyphenolic compound produced by a wide variety of plants. 
This compound has interesting functions namely as antioxidant, anti-inflammatory, 
anticarcinogenic, cell cycle inhibitor, anti-aging, cardioprotector, neuroprotector, 
obesity and diabetes preventive. The purpose of this study is to take advantage of the 
beneficial effects of resveratrol as a neuroprotector reducing the risk of 
neurodegenerative disorders, especially Alzheimer's disease and Parkinson's disease 
and reducing the risk of brain cancer due to its antioxidant, anti-inflammatory and 
anticarcinogenic activity. However the blood-brain barrier represents a considerable 
obstacle to brain entry of the majority of drugs and thus severely restricts the therapy 
of many serious central nervous system diseases. 
Furthermore, the pharmacokinetic properties of resveratrol are not favorable 
to its free administration, since the compound has poor bioavailability, low water 
solubility, and is chemically unstable.Therefore the aim is to develop a specific 
functionalized drug delivery system that protects resveratrol during its transit inside 
the organism until it reaches the target preserving its pharmacological properties and 
protecting from degradation and, at the same time, directing this drug to brain where 
it can exercise its neuroprotective effects. 
Solid lipid nanoparticles(SLNs) loaded with resveratrol were produced and 
successfully functionalized with ApoE since apolipoprotein E is sufficient to mediate 
the transport of NPs into the brain.The formulations were completely characterizedto 
evaluate the quality of the developed resveratrol-loaded nanoparticles for targeted 
brain drug delivery. 
TEM images revealed that these formulations produce two populations of 
nanoparticles, one that stands out clearly and is characterized by having a size well 
below (<150 nm), and other, less pronounced, but with a greater diameter (~200 
nm).Anaverage resveratrol entrapment efficiency over 90% was obtained for both 
SLNs with ApoE using DSPE or palmitate. Dynamic light scattering measurements gave 
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a Z-average of ~ 170 nm in the case of DSPE and a Z-average of ~ 200 nm in the case of 
palmitate with a PI of <0.2, and a reasonable negative zeta potential of around −13 
mV. These characteristics remained unchanged for at least 1 month. The release 
studies showed that the system is capable of providing a controlled and prolonged 
release of resveratrol with small losses of drug until it reaches its target (the brain). 
Functionalization of SLNs with ApoE was clearly demonstrated through 
fluorometric assays and evaluating the infrared spectra (using FTIR) for both types of 
functionalization performed. 
The results suggest that the functionalization of SLNs with ApoE resulted in 
dynamic stable systems capable of being used as controlled-release models for 
targeting brain delivery of resveratrol. Both functionalized nanodelivery systems (DSPE 
mediated and palmitate mediated) can be considered suitable carriers for resveratrol, 
conferring protection to this drug, targeting to the brain and allowing a controlled 
release after achieve the therapeutic target. 
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Resumo 
O resveratrol é um composto polifenólicoproduzido por uma grande variedade 
de plantas. Este composto apresenta funções bastanteatraentes do ponto de vista 
científico, nomeadamente como antioxidante, anti-inflamatório, anticarcinogénico, 
inibidor do ciclo celular, anti envelhecimento, cardioprotetor, neuroprotetor, 
prevenção de obesidade e diabetes e possível extensão do tempo de vida. O objectivo 
deste projeto é tirar partido dos efeitos benéficos de resveratrol como neuroprotector, 
reduzindo o risco de doenças neurodegenerativas, especialmente da doença de 
Alzheimer e doença de Parkinson, e reduzindo o risco de cancro do cérebro, devido às 
suas propriedades antioxidantes, anti-inflamatória eactividadeanticarcinogénica. 
Contudo, a barreira hematoencefálica representa um obstáculo considerável à entrada 
no cérebro da maioria dos medicamentos e, assim, restringe severamente o 
tratamento de muitas doenças graves do sistema nervoso central. 
Para além disso, as propriedades farmacocinéticas de resveratrol não são 
favoráveis à sua administração livre, uma vez que o composto apresenta uma fraca 
biodisponibilidade, baixa solubilidade em água e é quimicamente instável. Por 
conseguinte, o objectivo é desenvolver um sistema de entrega dofármaco 
funcionalizado que proteja o resveratrol durante o seu trajeto no interior do 
organismo até atingir o alvo, preservando as suas propriedades farmacológicas e 
protegendo-oda degradação e, ao mesmo tempo, dirigindo-o para o cérebro, onde 
poderá exercer os seus efeitos neuroprotetores. 
Nanopartículas sólidas lipídicas (SLNs) com resveratrol foram produzidas e 
funcionalizadas com sucesso com a ApoE3,uma vez que aapolipoproteína E3 é 
suficiente para mediar o transporte de nanopartículas para o cérebro. As formulações 
foram completamente caracterizadas para avaliar a qualidade das nanopartículas 
contendo resveratrol para a entrega do fármaco no cérebro. 
As imagens de TEM revelaram que estas formulações produziram duas 
populações de nanopartículas, uma que se destaca de forma clara e é caracterizada 
por ter um tamanho bastante inferior (< 150nm), e outra, menos pronunciada, mas 
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com um diâmetro maior (~200 nm). Uma eficiência de encapsulação de resveratrol 
superior a 90% foi obtida para os dois tipos de SLNs funcionalizadas com ApoE, usando 
DSPE ou palmitato. As medições de dispersão dinâmica de luz revelaramum tamanho 
médio de 170 nmno caso da funcionalização comDSPE, e de aproximadamente 200 nm 
no caso da funcionalização com palmitato, com um índice de polidispersão inferior a 
0,2 e umpotential zeta razoavelmente negativo de cerca de -13 mV. Estas 
características permaneceram inalteradas durante pelo menos 1 mês de 
armazenamento. Os estudos de libertação mostraram que o sistema é capaz de 
proporcionar uma libertação controlada e prolongada de resveratrol, com pequenas 
perdas de fármaco até este atingir o seu alvo (o cérebro). 
A funcionalização dasSLNs com a ApoE foi claramente demonstrada para ambos 
os tipos de funcionalizaçãodesenvolvidos, através de ensaios fluorimétricos e 
avaliando o espectro de infravermelhos das amostras (usando FTIR). 
Os resultados obtidos sugerem que a funcionalização dasSLNs com ApoE 
resultou em sistemas estáveis capazes de serem usadas como modelosde libertação 
controlada de resveratrol no cérebro. Ambos os nanossistemas funcionalizados 
(usando DSPE ou usando palmitato para adicionar a ApoE ao sistema) são inovadores e 
podem ser considerados como adequados para o transporte de resveratrol, conferindo 
protecção ao fármaco, direccionando-o para o cérebro e permitindo uma libertação 
controlada após atingir o alvo terapêutico.  
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Organization of the dissertation 
 
The dissertation is constituted by:  
 
1. Motivation and Objectives where basic necessary information provides a 
framework to the research topic, with an explanation why the subject was 
chosen for study, the description of the main and secondary goals of the 
dissertation, and the general organization of this dissertation; 
 
2. State-of-the-art where a relevant literature review is made on the subject 
of this work which includes: properties of resveratrol, problems in 
resveratrol pharmacokinetics, the potential of SLNs in brain drug delivery, 
the challenges of crossing blood-brain barrier (BBB) and namely the 
strategies of SLNs functionalization;  
 
3. Materials and Methods where is mentioned the list of materials used and 
their sources and all the methodologies used in the course of this work as 
well as its relevance to the work; 
  
4. Results and Discussion where the results are presented and accompanied 
by the respect discussion in the context of the literature review; 
 
5. Conclusions where it is summarized in some way the advantages and utility 
of the formulations developed. It is also presented the main conclusions 
based on the results obtained and the initial goals of this dissertation with a 
personal appreciation of the work developed. 
 
6. Future research is the last section where are described suggestions of 
possible future work that can be important for the current project. 
 
This dissertation has also an annex where all the supplementary results are included. 
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Motivation and Objectives 
 
Resveratrol is a natural polyphenolic phytochemical compound with a variety of 
bioactivities associated with prevention of diseases and health promotion. Recent 
works have proved that this compound has beneficial effects on neurological disorders 
such as neurodegenerative diseases, specially on their prevention. However, when 
resveratrol is administered in its free form it presents apoor bioavailability,a low 
solubility and is rapidly metabolized losing its therapeutic activity. Considering this, the 
amount of resveratrol that truly reach the brain would be almost residual.  
General and Specific objectives 
 
In this context, the aim of the current work is the development ofresveratrol 
loaded lipid nanoparticles for enhanced brain targeted drug delivery, taking advantage 
of the neuroprotective effects of resveratrol. SLNswill be employed in this study since 
they are known to be a promising drug delivery system to enhance brain uptake of 
many drugs and can easily be functionalized. The goal is to functionalize SLNs with 
apolipoprotein E (ApoE) in order to direct it to the brain because ApoE-modified 
nanoparticles could interact with apolipoprotein receptors (e.g. LDL receptor-related 
protein) at the BBB resulting in their endocytotic uptake into endothelium and 
trancytosis into the brain. 
Therefore, in order to accomplish the main objective of developing a valid 
functionalized nanocarrier system to encapsulate resveratrol, several other specific 
goals had to be established and achieved: 
 Optimization of nanoparticles to achieve an average size of 150 nm (the 
composition of particles and parameters of the modified hot 
homogenization technique for the production of SLNs had to be 
optimized, e.g. the amount of surfactant (polysorbate 80), the time of 
stirring, the time of sonication and the sonication intensity); 
 Functionalization of nanoparticles for targeting to the brain (ApoE as 
target to LDL receptor in BBB); 
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 Nanoparticles produced (with and without functionalization) were 
characterized by the determination of:(i) particle size measurements 
i.e., determination of the average hydrodynamic diameter and 
polydispersity index (PI) using dynamic light scattering (DLS); (ii) zeta 
potential measurements using electrophoretic light scattering (ELS); (iii) 
entrapment efficiency (EE) measured with UV-spectrophotometer; and 
(iv) morphology analyzed by transmission electron microscopy (TEM); 
 Evaluation of the nanoparticles stability during 2 months for SLNs with 
no functionalization and 1 month for functionalized SLNs, allowing to 
inferabout the nanoparticles shelf stability and the behavior of the 
nanoparticles during storage. The stability was verified over time by 
measuring the particles’ size,PI, zeta potential and entrapment 
efficiency; 
 To check and confirm the functionalization of the nanoparticles, we 
have performed fluorometric assays using a fluorescent probeand also 
infrared spectra of each sample in the Fourier transform infrared 
spectroscopy (FTIR) to verify the presence of specific functional groups 
characteristic of the functionalization; 
 Controlled release studies in simulated body fluid(SBF) were also 
performedto predict the release pattern of resveratrol in the 
bloodstream for both SLNs (with and without functionalization). 
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State-of-the-art 
 
Resveratrol 
 
Resveratrol (C14H12O3) is a natural polyphenolic antioxidant compound 
produced by a broad variety of plants and its structure is represented in figure 1. [1] 
Apart from all other sources, resveratrol may be found in high concentrations in the 
skin of grapes and their seeds. [2] This natural compound has been classified as a 
natural phytoalexin for being synthesized de novo by plants in response to injury, 
ozone exposure, UV irradiation and in response to fungal attack constituting a defense 
mechanism for the plant. [3-8] Resveratrol exists in cis and trans isomeric forms 
(represented in figure 1) although the trans-isomer is believed to be the most 
abundant and biologically active form.[9,11] 
 
 
 
 
French Paradox 
As mentioned before one of the richest natural sources of resveratrol is the 
dark grapes and consequently the wines that are produced from these grapes. 
Resveratrol became popular when the consumption of red wine was linked with the 
low incidence of cardiovascular diseases, a phenomenon commonly known as the 
French Paradox. It is believed that polyphenolic antioxidants offer protective effects 
for the cardiovascular system and in fact, certain populations of France, in spite of 
regular consumption of high fat diet and low exercise practice, appear to have less 
predisposition to heart diseases [1,12]. Is very interesting the fact that despite a high 
Figure 1 ● Chemical structures of resveratrol isomers.(A)trans-resveratrol and (B)cis-resveratrol. 
Resveratrol Loaded Lipid Nanoparticles for Brain Targeted Delivery 2013 
 
19  
 
level of risk factors (such as cholesterol, diabetes, hypertension and a high uptake of 
saturated fat), French males display the lowest mortality rate from ischemic heart 
disease and cardiovascular diseases in Western industrialized nations (36% lower than 
the USA and 39% lower than the UK). [13] 
Thus, a mild-to-moderate wine drinking habit attenuates cardiovascular, 
cerebrovascular, and peripheral vascular risks due to the reduced platelet adhesion. It 
also attenuates the risk of a variety of cancers including pancreatic, gastric, and thyroid 
cancer, and slows down some neurodegenerative diseases like Alzheimer’s disease and 
Parkinson’s disease. [10] 
Among approximately 500 different antioxidants (including resveratrol, 
catechin, epicatechin and proanthocyanidins.), recent studies revealed that resveratrol 
and proanthocyanidins are the two most important polyphenolic antioxidants present 
in wine that attenuate various health problems by reducing myocardial ischemic 
reperfusion injury.[14]In fact, resveratrol is the principal compound present in red wine 
that is responsible for French Paradox. 
Intracellular Activity of Resveratrol  
The interest of the scientific community in resveratrol has grown over the years 
due to due to its features and its wide biological and pharmacological activities at the 
cellular level which have been demonstrated. 
This phytoalexin has anticarcinogenic activity because it was able to positive 
modulate a huge variety of intracellular signaling molecules involved in multi-stage 
carcinogenesis, inflammation, cell cycle, and apoptosis by scavenging of free radicals, 
suppression of cyclooxygenaseactivity, inhibition of cell proliferation, induction of 
apoptosis, and inhibition of enzymes, namely ribonucleotidereductase, DNA 
polymerases and protein kinase C. Associated with this anticarcinogenic activity come 
the potential of resveratrol as antioxidant by scavenging radicals like hydroxyl, 
superoxide, and others, protecting cell membranes against lipid peroxidation and 
avoiding DNA damage caused by the generation of reactive oxygen species (ROS).[1] On 
the other hand resveratrol has shown to exhibit anticarcinogenic effects also due to 
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anti-inflammatory activity of this compound by blocking the expression of various 
components of pro-inflammatory signaling (such as iNOS, IFN-ɣ, pro-inflammatory 
cytokines and TNF-α), through the suppression of nuclear factor-KB (NF-KB) and the 
activator protein-1 (AP-1).[1,11] Thereby, its anti-inflammatory and antioxidant activity 
jointly with the potential to induce cell cycle arrest and apoptosis are responsible for 
the chemopreventive effects of resveratrol.[1] 
As already mentioned resveratrol has cardioprotective effects associated with 
the French Paradox. Several mechanisms have been suggested to explain this 
cardioprotective effect of resveratrol which include, for example, the ability to inhibit 
the secretion of catecholamines that contribute to the increased risk of heart failures, 
atherosclerosis, coronary heart disease and hypertension;  to modulate the production 
of NO from vascular endothelium which might control the inflammatory responses and 
prevent vascular damage (by inhibiting NF-KB that regulates iNOS expression in 
endothelial cells); and to inhibit eicosanoid synthesis from arachidonic acid that leads 
to the decrease of platelet aggregation.[1]  This anti-aggregating effect of resveratrol 
inhibit thrombus formation (atherosclerosis protection). In this case, as proved by 
Bertelli, cis-resveratrol was able to decrease collagen-induced platelet aggregation 
while trans-resveratrol at the same concentration showed a slightly lower activity. [9] 
Beyond the anticarcinogenic and cardioprotective effects, resveratrol has been 
shown to have neuroprotective effects in some neurological disorders, such as 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, brain ischemia, and 
epilepsy.[1,21] Promising data within the use of resveratrol have been obtained by Saiko 
and his team, regarding the progressive neurodegenerative diseases such as 
Alzheimer, Huntington, and Parkinson. Because neurotoxicity is often related to 
mitochondrial dysfunction and may be ameliorated through the inclusion of metabolic 
modifiers and/or antioxidants, resveratrol may provide an alternative intervention 
approach that could prevent further damage and act at the level of prevention of brain 
diseases.[17] Indeed moderate consumption of wine is associated with a lower 
incidence of Alzheimer's disease because wine is enriched in antioxidant compounds 
(like resveratrol) with potential to neuroprotective activities.[18] In Alzheimer’s disease, 
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resveratrol seems to lower the levels of secreted and intracellular Aβ peptides 
produced by different cell lines. In fact resveratrol does not inhibit Aβ production, 
because it has no effect on the Aβ-producing enzymes beta- and gamma-secretases, 
but promotes instead the intracellular degradation of Aβ peptides via a mechanism 
that involves the proteasome.Thus this natural compound has not only a preventive 
effect in Alzheimer’s disease but also a therapeutic potential by its activity in 
proteasome-dependent anti-amyloidosis. [18] 
Relatively to Parkinson’s disease, resveratrol exerts a neuroprotective effect on 
6-hydroxydopamine-induced Parkinson rat model, and this protection is related to the 
reduced inflammatory reaction.[19] Kwok-Tung Lu showed that resveratrol 
administration significantly protect mice from hydroxyl radical overloading, neuronal 
loss and motor coordination impairment induced by MPTP that is the most useful 
neurotoxin to induce Parkinsonism.[20] 
Recently, resveratrol was shown to extend life span in yeast through the 
activation of longevity gene SIRT1, which is also responsible for the longevity mediated 
by calorie restriction. In fact resveratrol mimics calorie restriction through the 
induction of expression of several longevity genes. These longevity genes include SIRTs 
and FOXOs that act coordinately for the regulation of cell survival and longevity.[10] 
Apart from all the therapeutic properties already described, resveratrol has 
been shown to present beneficial effects also in obesity and diabetes, causing 
changes in gene expressions and in enzyme activities contributing to the prevention 
and treatment of insulin resistance, type II diabetes or dyslipidemia. [1,16] 
As we can see resveratrol may be useful in treating cardiovascular diseases, 
cancers, pain, inflammation, tissue injury, and in reducing the risk of 
neurodegenerative disorders, especially Alzheimer's disease and Parkinson's disease. 
The aim of this project is to take advantage of the neuroprotective effects of 
resveratrol to prevent the development of several neurological disorders that can have 
serious repercussions in terms of physical and mental health. 
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Problems in pharmacokinetic  proprieties of resveratrol  
 Unfortunately, the pharmacokinetic properties of resveratrol are not as 
favorable when compared with its beneficial pharmacological activities in various 
disease models. This polyphenol has high oral absorption but is rapid and extensive 
metabolized resulting in only trace amounts of unchanged resveratrol in the systemic 
circulation.To give an idea,in humans, about 70 % of orally administered resveratrol 
(25 mg) is rapidly absorbed and metabolized (< 30 min). [1] However we should also 
remember that there are some genetic aspects concerning ethnicity and genetic 
polymorphisms that affect the metabolism of compounds, existing variability in the 
time of drug metabolism. Extremely rapid sulfate conjugation in liver appears to be the 
rate-limiting step in resveratrol’s bioavailability. Even though the systemic 
bioavailability of resveratrol is very low, the accumulation of resveratrol in epithelial 
cells along the aerodigestive tract and potentially active resveratrol metabolites may 
still produce cancerpreventive and other biological effects with much less efficiency.[22] 
 The lipophilicity is one of the intrinsic properties of many drugs that influence 
the penetration of the drug molecule into the cell and consequently their ability to 
achieve the appropriate intracellular targets. Resveratrol has a partition coefficient of 
3.1 (log P) being a hydrophobic drug. Substances very poorly soluble in water lead to 
low absorption and poor bioavailability in case of oral administration and may 
aggregate after intravenous administration leading to complications such as embolism 
or local toxicity. 
In addition, the use of resveratrol is limited because it is a compound easily 
oxidizable and extremely photosensitive undergoing a transformation induced by light 
(UV) from the trans isomer to the cis isomer. 
However the aim of this work was to take advantage of the neuroprotective 
effects of resveratrol and for this purpose the compound needs to reach the brain. If 
the compound was administered in its free form, little or no drug would reach the 
brain due to its low bioavailability, low water solubility, and its chemical instability 
which would lead to a rapid and extensive metabolization and excretion.[2] 
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Therefore the development of specific functionalized drug delivery systems that 
protect resveratrol during its transit inside the organism until it reaches the target is 
extremely relevant to preserve its pharmacological properties protecting from 
degradation and at the same time directing this drug to brain where it can exercise its 
neuroprotective effects. 
Nanoparticles for resveratrol delivery 
 
 The main advantages of using nanoparticles as drug delivery systems are the 
possibility of minimizing degradation of a drug after its administration and maximizing 
the therapeutic effects reducing unwanted side effects. With nanoparticles we can also 
increase the bioavailability of drugs and drive (by active or passive target) the drugs to 
the site of action increasing, in a specific or non-specific way, the concentration of a 
drug in the area of pathology. Moreover, the nanoparticle system has to be non-toxic 
(biodegradable, biocompatible, non bioaccumulative and non-immunogenic); have a 
small and controlled size; a large surface-volume ratio resulting in an increase of locals 
of interaction and locals to functionalize; a surface charged to prevent aggregation and 
increase the stability of the particles in solution; a high capacity to contain and carry a 
large amount of drug; and finally, like every product, must be economically viable and 
easily prepared.  
 Ideally nanoparticles for therapeutic usage should remain in circulation for an 
adequate time and be present at the site of action in adequate amounts to promote a 
controlled drug release and an efficient uptake by cells for improving the therapeutic 
efficacy. 
 
Solid Lipid Nanoparticles (SLNs) 
 
In the sequence of the work done by Neves et al.[2], the vehicle for resveratrol 
transport developed was the SLNs which constitute an attractive colloidal resveratrol 
carrier system with very potential also for brain targeting.  
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SLNs consist of spherical solid lipid nanoparticles in the 
nanometer range, which are dispersed in water or in aqueous 
surfactant solution. SLNs are produced from solid lipids 
producing a solid matrix with few cavities at room and body 
temperatures (figure 2). They are made of one or more lipids 
with melting points higher than body temperature, so this 
carrier remains in solid state after administration. 
These carriers have a hydrophobic core being specially adapted to the transport 
of hydrophobic drugs such as resveratrol.  These controlled-release systems are 
suitable for transporting and protecting this important bioactive compound against 
degradation, increasing its physical stability and have a special ability to penetrate cell 
membranes, allowing the increased cellular uptake of compounds they are loaded 
with. [2,26] 
SLNs are very promising since they combine a variety of advantages: [26] 
 They are composed of biodegradable and biocompatible excipients 
(“GRAS” Lipids - generally recognized as safe, FDA); 
 This is a water based technology, avoiding organic solvents that may be 
a focus of toxicity; 
 These systems have a high physical stability; 
 SLNs in a range of 120-200 nm are not taken up readily by the cells of 
mononuclear phagocyte system (MPS) and thus bypass liver and spleen 
filtration; 
 It can be achieved a controlled release of the incorporated drug for up 
to several weeks; 
 It is possible to functionalize the surface directing the drug to its site of 
action (maximizing therapeutic effects and minimizing side effects); 
 Depending on the composition and preparation they may be quite 
stable over time; 
 It can be achieved a high entrapment efficiency, depending on the drug 
lipophilicity properties; 
Figure 2 ● Illustrative 
structure of SLNs. 
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 This is a delivery system economically more affordablethan others 
because it is easy to scale-up due to itsfacilityof preparation and 
reproducibility.  
 
Therefore, SLNs have a lot of advantages as a system for drug delivery, namely 
for lipophilic compounds. However, our aim is that nanoparticles reach the brain, so 
we need to develop a specific target to BBB permeation. In the late 90s SLNs were 
proposed for brain drug targeting application even though the first proof of lipid 
particle transport across the BBB had already been provided.[31] 
Polymeric nanoparticles have been characterized as a good vehicle to deliver 
drugs into the brain although there are various problems associated with the use of 
these nanoparticles like residual contamination from production process (organic 
solvents), polymerization initiation, large polymer aggregates, toxic monomers and 
toxic degradation products, expensive production methods, lack of large scale 
production method and suitable sterilization method. [26] Lipid-based nanocarriers hold 
strong promise to delivery of drugs to central nervous system(CNS)because these 
materials are biocompatible and biodegradable as already mentioned and because the 
lipophilic materials have the natural tendency to target through BBB. [27] Several 
studies have been made to direct drugs to brain and there are other important 
features which makes the SLNs as appealing: 
 Due to its lipid nature (lipophilic) SLNs have the natural tendency to 
cross the BBB;[27] 
 The SLNs appear suitable as a drug carrier system for potential 
intravenous use due to their very low cytotoxicity in vitro (SLNs cause 
less non-specific cell toxicity even compared to nanoparticles made of 
PLGA);[28] 
 P-gp efflux activity at brain endothelial cells can be bypassed using SLN 
formulations;[29] 
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Thus, SLNs evidently hold strong promise for brain delivery of drugs and this 
was the carrier chosen for the developmentof a new brain targeted resveratrol 
delivery system.  
For the preparation of SLNs it is necessary the use of one or more surfactants 
that stabilize the lipids in aqueous solution and allow the formation of spherical 
nanoparticles. However the type of surfactant used can be crucial to the success of the 
formulation since it determines the type of plasma proteins that will adsorb in the 
surface of the nanoparticles when they are administered. The composition of the 
protein layer is regarded as the decisive factor, for example immunoglobulin G is 
known to be a specific activator of the complement system promoting recognition and 
phagocytic uptake of particulate carriers by MPS, whereas albumin creates a more 
hydrophilic surface which was found to reduce the phagocytic uptake in vivo.[32] 
Other surfactants are active in producing protein binding by the nanoparticles, 
but only polysorbate 80 appears to preferentially adsorb Apo-E.[30] In fact, polysorbate 
80 coated polybutylcyanoacrylate nanoparticles showed a preferentially adsorbing 
ApoE on their surface when compared with other surfactants. Due to ApoE adsorbed 
on the surface, accumulation in the brain might occur because the LDL receptors are 
overexpressed in BBB and recognized the ApoE-modified nanoparticles. By this way 
polysorbate 80-stabilized SLNs might have the biggest potential of delivering drugs into 
the brain.[32]In fact, nanoparticles coated with polysorbates have previously been 
shown to enable the transport of several drugs across the blood-brain barrier, which 
under normal circumstances is impermeable to these compounds.[34] 
However, Zensihas shown that maybe polysorbate 80 coating is not enough to 
induce the crossing over BBB because after 30 minutes of incubation with the 
nanoparticles only the nanoparticles with covalently bound ApoE were detected in 
brain capillary endothelial cells and neurons.[25] No uptake into brain was detectable 
with nanoparticles with no ApoE despite having been reported. 
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Nevertheless the surfactant chosen for SLNs preparation was polysorbate 80 
but to direct them to the brain it is necessary to add an active target so that our 
resveratrol delivery system can be effective. 
Directing to Blood-brain barrier… 
 
The BBB is a dynamic barrier protecting the brain against pathogenic organisms 
and unwanted substances. As a dynamic system the BBB is capable of responding to 
local changes and requirements and is able to be regulated via a number of 
mechanisms and cell types, in both physiology and pathological conditions. [23]However 
BBB represents a considerable obstacle to brain entry of the majority of drugs and thus 
severely restricts the therapy of many serious CNS diseases including brain tumors, 
brainHIV, Alzheimer and other neurodegenerative diseases. Therefore, only small 
(MW<500 Da) and lipophilic molecules can penetrate into the vascular space. The two 
main reasons for the failure of the drug delivery to the brain are (i) the poor 
penetration of the drug molecule across the BBB that is related with the 
physicochemical characteristics of the therapeutic agent (like lipophilicity) and with the 
drug related factors at the BBB as concentration, the size, conformation, ionization, 
and others; (ii) the back transport of drugs from the brain to the blood that depend on 
the affinity for efflux mechanisms.[26] There are several membrane transporters 
located in the barrier which mediate the molecules efflux from the CNS compartment 
back to the blood and most of these transporters belong to the superfamily of ATP-
binding Cassette (ABC) membrane transporters. These are the most ubiquitously 
expressed and largest membrane-associated proteins superfamily known to date and 
they are involved in the translocation of both endogenous and exogenous substrates 
and metabolites against their concentration gradient. P-glycoprotein (P-gp) is probably 
the most studied and characterized ABC member and is known to be involved in the 
cellular extrusion of a broad range of drugs, having many kinds of substrates.[27] 
There are many strategies that have been proposed to improve the 
permeability of drugs across the BBB which include:[27] 
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 Inhibition of ABC transporters, once it has been developed a number of 
chemical entities of blocking specific ABC-transporters (e.g. P-gp 
inhibitor); 
 Hyper-osmotic opening of the BBB, once it is known that an hypertonic 
solution of mannitol or urea can shrink the capillary endothelial cells by 
inducing water efflux and subsequently opening the tight junctions 
network momentarily; 
 Pharmacological disruption of BBB using cytotoxic agents especially 
alkylating agents (etoposide or cisplatin) that disrupt tight junctions and 
create openings between the endothelial cells; 
 Drug modification approach creating pro-drugs with good lipophilicity 
that can cross the cell membrane of the endothelial cells by passive 
diffusion; 
 Nanotecnology for drug delivery to the brain that with its flexibility and 
versatility can direct the drug to the target site and at the same time it is 
possible to reduce the dosing frequency using a carrier that releases the 
drug in a sustained manner. 
 
This work intends to take advantage of nanotechnology developing solid lipid 
nanoparticles to increase the concentration of resveratrol in the brain which may exert 
its therapeutic effect. To cross this barrier extremely organized in the brain 
nanoparticles size must be a focal point. SLNs of a size below 200 nm have an 
increased blood circulation and thus an increase in the time for which the drug 
remains in contact with BBB and for the drug to be taken up by the brain. [26] 
Additionally the delivery process can be made more selective and efficient by 
tagging the nanocarrier surface with ligand molecules that match with a receptor type 
that is strongly and specifically expressed on the surface of the cells to be targeted. 
This is a highly regulated and energy-dependent process, but may allow the whole 
nanocarrier and the loaded drug to go through the BBB, even passing the drug efflux 
transporters.[27] Especially ApoE appears to play a major role in the nanoparticle-
mediated drug transport across the BBB, as mentioned before.[33] 
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 Following this, we propose directing our resveratrol loaded SLNs to LDL 
receptors in the brain by covalently bound ApoE to the SLNs surface.  
LRP1 (low-density lipoprotein receptor related proteins 1) and LRP2 (low-
density lipoprotein receptor related proteins 2) are multifunctional, multi-ligand 
scavenger and signaling receptors, widely expressed in several tissues, and together 
they can interact with a very diverse range of molecules and mediators including ApoE. 
This apolipoprotein plays an important role in the transport of lipoproteins into the 
brain via LDL receptors.[32]It is believed that the lipoprotein ApoE bound on 
nanoparticles surfaces, followed by LDL receptor mediated endocytosis and 
transcytosis facilitate the uptake of nanoparticles by the brain. [24] 
It has already been shown that the use of nanoparticles attached ApoE enabled 
the delivery of drugs across the BBB. In their study, Zensi produced PEGylated albumin 
nanoparticles with covalently bonded ApoE that enhanced uptake and intracellular 
localization in mouse endothelia cells. Thus nanoparticles with covalently 
bound ApoE are able to be taken up into the cerebral endothelium by an endocytic 
mechanism followed by transcytosis into brain parenchyma.[25] Wagner and his group 
studied the uptake mechanism of ApoE-modified nanoparticles and clearly 
demonstrated the participation of LDL receptor family members, especially LRP1, on 
the specific ApoE-mediated nanoparticle uptake on brain endothelial cells. 
 In Caucasian populations there are three common variants of ApoE: ApoE2, 
ApoE3 and ApoE4. ApoE3 is the most frequent one, followed by ApoE4 and 
ApoE2.Within the ApoE family, ApoE3 and ApoE4 showedan higher binding affinity to 
the LDL receptor when compared to the other because ApoE2 is defective in binding to 
lipoprotein receptors presenting, for example, a <5% LDL receptor binding when 
compared with ApoE3 binding. Michaelis et al. showed that ApoE3 alone is sufficient to 
mediate loperamide transport to the brain by the specific event of recognition and 
binding to LDL receptors. ApoE-coupled nanoparticles may mimic lipoprotein particles 
(like LDL) that are endocytosed into the BBB endothelium and transcytosed through 
the BBB endothelium into the brain. [34,35]Therefore, SLNs coupled to ApoE3 would be 
sufficient to mediate the transport of resveratrol into the brain. 
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Materials and Methods 
 
Materials  
For the nanoparticles synthesis, trans-resveratrol (more than 99% pure) was 
purchased from Sigma-Aldrich (St Louis, MO, USA), the solid lipid cetylpalmitate was 
provided by Gattefossé (Nanterre, France) and polysorbate 80 (Tween® 80) was 
supplied by Merck (Darmstadt, Germany). For the preparation of pH 7.4 phosphate 
buffer solutions, potassium phosphate monobasic was obtained from Sigma-Aldrich 
and sodium hydroxide from Riedel-de Haën (Seelze, Germany).  
For the nanoparticles functionalization, sodium deoxycholate, avidin, NHS-
palmitate, EDC and ApoE3 were provided by Sigma-Aldrich (St Louis, MO, USA), DSPE-
PEG-NH2 was purchased from Avanti Polar Lipids (Alabaster, Alabama, USA), and the 
biotinylation reagent [EZ-Link Sulfo-NHS (N-hydroxysuccinimido)-Biotin], the Snakeskin 
10kDaMWCO dialysis tube, and the Slide-A-Lyzer Dialysis Cassette (10 kDa MWCO) 
were supplied by Thermo Scientific (Waltham, Massachusetts, USA). 
 For fluorometric assays, the fluorescein biotin was obtained from Life 
Technologies (Van Allen Way, Carlsbad, USA). 
 In preparation of SBF for resveratrol release studies dipotassium phosphate 
[K2HPO4]was purchased from Sigma-Aldrich (St Louis, MO, USA); calcium chloride 
[CaCl2], sodium sulfate [Na2SO4] andtris(hydroxymethyl)aminomethane 
[(CH2OH)3CNH2]were supplied by Merck (Darmstadt, Germany); sodium chloride 
[NaCl], magnesium chloride [MgCl2] and sodium bicarbonate [NaHCO3] were obtained 
from Riedel-de Haën (Seelze, Germany); potassium chloride [KCl] was purchased from 
Scharlau Chemie S.A. (Sentmenat, Barcelona, España); and finally, hydrochloric acid 
[HCl] was supplied by Panreac Química (Castellar del Valles, Barcelona, España). 
The water used in all experiments during this project was purified water by 
Ultra-pure water system (Milli-Q RG), and was obtained from a reverse osmosis 
process. 
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Figure 3●Preparation method of SLNs. 
Preparation of SLNs  
The method chosen for the preparation of the nanoparticles was a good 
compromise between the high shear homogenization to produce particles in the 
micrometer range and the ultrasound method to reduce the microparticles to the 
nanometer range, see figure 3.  
The lipid phase, containing cetylpalmitate (solid lipid), the stabilizer polysorbate 
80, and the lipophilic resveratrol to be encapsulated (0, 2, 5, 10, or 15 mg) was melted 
at 70°C, which was above the lipid’s melting point. The molten lipid was then dispersed 
in phosphate bufferpH 7.4, at the same temperature by high-speed stirring in an Ultra-
Turrax T25 (Janke and Kunkel IKA-Labortechnik, Staufen, Germany) followed by 
sonication using a Sonics and Materials Vibra-Cell™ CV18 (Newtown, CT, USA).The 
mechanical shearing forces produced by the high-speed stirring in the Ultra-Turrax T25 
produced a “pre-emulsion” of the lipid melt and aqueous surfactant producing 
particles in the micrometer range, while the sonication reduced the microparticles 
sizes to the nanometer range. [36] 
Some parameters of the high shearhomogenization and ultrasound method 
technique for the lipid nanoparticles production were optimized in order to establish 
the best conditions for the production of formulationin terms of stability and 
optimization of average size (<200 nm). The content in solid lipid and surfactant was 
also tested in order to optimize the size and stability of the nanoparticles. After this 
previous optimization, the final parameters chosen were 120 seconds at 12,000 rpm in 
Ultra-Turrax, followed by 15 minutes of 80% intensity sonication and a percentage of 
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Figure 4●Activation of avidin with EDC performed at room temperature for 30 
minutes with stirring. 
polysorbate 80 of 3%. All thecomponents of the formulations were weightedin an 
analytical balance (Mettler Toledo AG285). 
The formulations appeared white and milky and had low viscosity. The cooling 
of the nanoemulsions at room temperature allowed the crystallization of the lipid and 
subsequent formation of the lipid nanoparticles. To assess the stability of the 
formulations, they were stored at least for 1 month at 10 °C and the particle size, zeta 
potential and entrapment efficiency were measured periodically. 
Functionalization of Nanoparticles  
The challenging functionalization with ApoE takes advantage of the strongest 
known non-covalent interaction (Kdof 10
-15 M) between a protein and ligand: the 
avidin-biotin complex. The bound formation between biotin and avidin is very rapid, 
and once formed, is unaffected by extremes of pH, temperature, organic solvents and 
other denaturing agents. Avidin is a tetrameric protein and has a very high affinity for 
up to four biotin molecules.Therefore, the functionalization of nanoparticles was 
performed by two different strategies: (i)using DSPE-PEG-avidin conjugated to the 
nanoparticles and (ii)using avidin palmitate conjugated to the nanoparticles. The 
avidin-conjugated nanoparticles then react with the previously biotinylated ApoE 
producing ApoE-functionalized SLNs. 
Strategy I: Preparation of SLNs with DSPE-PEG-Avidin 
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Figure 5●Peptide bond formation between avidin and DSPE nanoparticles to form nanoparticles 
(NP’s) conjugated with avidin. The reaction was performed at room temperature during 2 hours. 
In this case, SLNswere prepared from the beginning as described above with 
the incorporation of DSPE-PEG-NH2 in their composition. At the same time avidin 
solution was prepared at a concentration of 5 mg/ml by the dissolution of avidin in 
PBS. Avidin was later activated by incubation with EDC (in a ratio of 5:1, respectively)at 
room temperature for 30 minutes with stirring (figure 4).  
After that, DSPE-containing nanoparticles (with a terminal amine group 
exposed on surface) were incubated at room temperature for 2 hours with the 
solution of avidin previously prepared and activated with EDC,giving rise to the 
nanoparticles conjugated with avidin (figure 5).The resulting nanoparticles were then 
dialysed in a snakeskin dialysis tubing MWCO 10 kDa against PBS, overnight at 37 °C, to 
remove the excess of avidin. 
 
Strategy II: Preparation of SLNs with avidin palmitate 
The avidin solution was firstly prepared at a concentration of 5 mg/ml by the 
dissolution of avidin in sodium deoxycholate (2%, pre-diluted in PBS). This solution was 
heated at 37°C with stirring until complete dissolution. NHS-palmitate was then added 
to the above solution and placed in an ultrasonic bath at 37°C until all palmitate flakes 
are dissolved. In order to promote the binding of avidin to palmitate, the solution 
formed was placed in a bath at 37°C for 3 hours (figure 6) and then dialysed in a 
dialysis tubing MWCO 10 kDa snakeskin against sodium deoxycholate (2%) at 37°C 
Resveratrol Loaded Lipid Nanoparticles for Brain Targeted Delivery 2013 
 
34  
 
Figure 7● Mechanism of conjugation between biotin and ApoE. 
Figure 6●Binding of avidin to palmitate, performed at 37°C, during 3 hours to form avidin-palmitate. 
overnight to remove excess avidin. Finally, the lipid nanoparticles were prepared as 
previously described but incorporating palmitate avidin in their constitution. 
Biotinylation of ApoE 
ApoE solution was prepared by dissolving it in PBS to a final concentration of 
0.2 mg/ml. Then,it was added the biotinylation reagent (sulfo-NHS-biotin) to the ApoE 
solution (in a ratio of 1:7, respectively), and it was incubated for 4 hours at 4°C, giving 
rise to biotinylated ApoE, see figure 7. Afterwards it was necessary to dialyse the 
solution of biotinylated ApoE to remove excess biotinylation reagent and ApoE that 
was not bound to the biotin. The dialysis was performed in a Slide-A-Lyser Dialysis 
Cassette (10 kDa MWCO) in 500 ml PBS, at 4°C for 8 hours, with medium change every 
two hours.  
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Binding of biotinylated ApoE to SLNs conjugated with avidin 
The binding of biotinylated ApoE to avidin conjugated SLNs was carried out by 
the spontaneous interaction of biotin and avidin, promoted by the simple contact 
between the two solution, for 30 minutes at room temperature.This strong interaction 
is the basis for the successful functionalization of nanoparticles with ApoE in order to 
direct them to the BBB and to promote the controlled release of resveratrol in CNS. 
 In order to check and confirm the functionalization of SLNs, we have 
performed fluorometric assays using a fluorescent probe  (fluorescein biotin) and also 
infrared studies using FTIR, shown later in this chapter. 
 
Morphology determination 
 
To characterize the morphology of SLNs (with and without functionalization), 
the nanosystems were observed by TEM. 
TEM utilizes energetic electrons to provide morphologic, compositional and 
crystallographic information of the samples. This equipment produces a high-
resolution (maximum magnification of 1 nm), two-dimensional, black and white 
imagesresulting ofthe interactions that takes place between the prepared samples and 
the energetic electrons in the vacuum chamber. Air needs to be pumped out of the 
vacuum chamber to create a space where electrons are able to move. 
The samples were mounted on 300 mesh form var copper grids, stained with 
uranyl acetate, and were examined using a Jeol JEM 1400 transmission electron 
microscope (Tokyo).  Images were digitally recorded using a Gatan SC 1000 ORIUS CCD 
camera (Warrendale, PA, USA), and photomontages were performed using Adobe 
Photoshop CS software (Adobe Systems, San Jose, CA). 
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Particle Size measurements 
Particle size analysis was performed by DLS, also known as photon correlation 
spectroscopy, using a particle size analyzer (Brookhaven Instruments, Holtsville, NY, 
USA).  
This equipment is an important tool for measuring the size of nanoparticles in 
solution. DLS measures the light scattered from a laser that passes through a colloidal 
solution like shows figure 8.When a beam of light intersects a nanoparticle, part of the 
incident light is scattered. Moreover, nanoparticles in suspension are in constant 
motion (Brownian motions) due to the fact that small particles move randomly in 
solution as a consequence of the shocks between the fluid molecules and the particles 
in solution. Thus, this Brownian motions causes changes in scattered light intensity and 
by measuring the fluctuations of the scattered light intensity as a function of time, the 
DLS technique can give information about the mean hydrodynamic size (that 
includethehydrationspherethat surroundsthe particles), size distribution and PI of 
nanoparticles in suspension.PIis a measure of size variability, a unitless quantity 
derived from the commutations analysis and equivalent to the relative variance of the 
distribution that indicates the state of particle agglomeration. Thus, DLS does not 
directly measure the diameter of particles, but rather detects the fluctuations of light 
signals caused by the Brownian motion of the particles to calculate their sizes. [37] 
As we can see in figure 8 larger particles will diffuse slower than smaller 
particles and the DLS instrument measures the time dependence of the scattered light 
to generate a correlation function that can be mathematically linked to a particle size 
and PI.  
Prior to the measurements, all samples were diluted (1:200) using phosphate 
buffer pH 7.4to yield a suitable scattering intensity. The average count rate was always 
between 100 and 500 kcps, showing that the dilution applied to the formulations was 
appropriate. DLS data were analyzed at 10°C and with a fixed light incidence angle of 
90°. The mean hydrodynamic diameter (Z-average) and the PI were determined as a 
measure of the width of the particle size distribution. The Z-average and PI of the 
analyzed samples were obtained by calculating the average of ten runs. The 
measurements were always performed in triplicate. 
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Figure 8●Scattering effect: when a beam of light falls on a nanoparticle the incident light is 
scattered depending on the particle size. 
 
Zeta Potential measurements 
The zeta potential was determined by measurement of the electrophoretic 
mobility using a zeta potential analyzer (Brookhaven Instruments, Holtsville, NY, USA).  
The liquid layer surrounding the particle is formed by two parts: an inner 
region, called the Stern layer, where the ions are strongly bound; and an outer, more 
diffuse region where the ions are less firmly attached. Within the diffuse layer there is 
a notional boundary inside which the ions and particles form a stable entity. When a 
particle moves, ions within the boundary move with it, but any ions beyond the 
boundary do not travel with the particle. This boundary is called the surface of 
hydrodynamic shear and the potential that exists at this boundary is known as the zeta 
potential.[38] 
ELS is a technique to measure the zeta potentialof a sample placed in a cell with 
electrodes. Then, an electric field is applied and the charged particles of the sample 
are attracted to the electrode of opposite charge.The laser passes through the sample, 
occurring electrophoresis and the frequency of light scattering caused by the particle is 
deflected. The frequency’s deviation of the scattered light is proportional to 
electrophoretic mobility of the particles and therefore to the zeta potential. 
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The magnitude of the zeta potential gives an indication of the potential stability 
ofthe colloidal system.If all the particles have a very negative or very positive charge 
they will repel each other and therefore the dispersion has a good stability. If particles 
have a low zeta potential, there will be agglomeration and consequently instability in 
the dispersion. 
Samples were diluted (1:200) with phosphate buffer (pH 7.4) and were analyzed 
at 10°C. The zeta potential of the analyzed samples wasobtained by calculating the 
average of ten runs (each one with ten cycles). The measurements were performed 
always in triplicate. 
 
Resveratrol Entrapment Efficiency (EE)  
The EE of the drug was determined by calculating the difference between the 
total amount of resveratrol used to prepare the formulation and the amount of free 
resveratrol that was still present in the aqueous phase. The formulation samples were 
diluted in phosphate buffer (1:200) and transferred into Amicon® Ultra-4 Centrifugal 
Filter Devices (Millipore, Billerica, MA, USA). Centrifugation was performed using a 
Jouan BR4i multifunction centrifuge with a KeyWrite-D™ interface (Thermo Electron, 
Waltham, MA, USA) with a fixed 23°-angle rotor and 3300 g spin for 10 minutes. The 
unentrapped resveratrol was present in the supernatant, which was stored in the 
centrifuge tube and quantified using a V-660 spectrophotometer (Jasco, Easton, MD, 
USA) at 200–600 nm. The EE wascalculated as follows: 
𝐸𝐸 =
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙 –𝑈𝑛𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑟𝑒𝑠𝑣𝑒𝑟𝑎𝑡𝑟𝑜𝑙
 × 100 
 
In vitro resveratrol release studies  
The in vitro resveratrol release studies were performed using a cellulose dialysis 
bag diffusion technique (Cellu.Sep® T1 with a nominal molecular weight cut off of 3500 
[Frilabo, Milheirós, Maia, Portugal]) filled with 2 mL of the sample (SLN 0, 2, 5, 10 and 
15 mg of resveratrol). 
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We were interested in simulating the bloodstream conditions that would occur 
following intravenous administration to simulate the release of resveratrol from 
nanoparticles during the time that the nanoparticles take to reach their target (BBB). 
Kokubo and his colleagues developed an acellular SBF that has inorganic ion 
concentrations nearly equal to those of human blood plasma and is buffered at pH 7.4 
with 50 mMtrishydroxy-methylaminomethane and 45 mM hydrochloric acid at 
36.5°C.[39,40] 
For both nanoparticles (SLNs with and without functionalization) the samples 
were incubated for 28 hours in SBF at body temperature (37°C) while being stirred at 
100 rpm. At regular intervals, aliquots were collected and replaced with the same 
volume of fresh medium of SBF to maintain the sink conditions. The resveratrol release 
was quantified using a V-660 spectrophotometer (Jasco, Easton, MD, USA) at 200–600 
nm. The studies were conducted in triplicate and the cumulative percentage of 
released compound was determined by calculating the average, indicating the 
standard deviations (SDs). 
 
Lyophilization 
Samples of SLNs with and with no functionalization were lyophilizated using an 
Advantage 2.0 benchtop freeze dryer (SP Scientific, Mearns Road Warminster, PA, 
USA). Lyophilization is a dehydration process that removes water and other solvents by 
the process of sublimation.This process was employed in order to use the samples in 
FTIR experiments because otherwise the water bands could mask the ones related to 
the sample itself. The lyophilization process started with freezing the samples 
processed at -60°C in vacuum for a period of 720 minutes for the water contained in 
the sample pass into a solid state and can sublimate with the increase of temperature. 
Then, there wasa drying of the samples at 20°C for 1200 minutes at 150 millitorr. 
Finally it took place a secondary drying at 25°C for 1200 minutes at 100 millitorr to 
increase the amount of sublimated water. 
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Figure 9●FTIR equipment. 
FTIR 
To show and confirm the presence of ApoE in functionalized SLNs we have 
done infra-red spectra for each lyophilized samples using FTIR (see figure 9).  
Infrared spectra result from transitions between quantized vibrational energy 
states. Molecular vibrations can range from the simple coupled motion of the two 
atoms of a diatomic molecule to the much more 
complex motion of each atom in a large 
polyfunctional molecule. The degrees of freedom 
give the number of ways that the atoms in a 
nonlinear molecule can vibrate and for many 
vibrational modes only a few atoms have large 
displacements and the rest of the molecule is 
almost stationary. The frequency of such modes is 
characteristic of the specific functional groups in which the motion is 
centered. Therefore, the observation of spectral features in a certain region of the 
spectrum is often indicative of a specific chemical functional group in the molecule and 
by analyze the absorptions bands that is given in the infrared spectrum is possible to 
identify vibrational modes associated with a certain functional group. [41] 
Besides the presence of functional groups, it is also possible to identify 
entiremolecules because the infrared spectrum of a given molecule is unique and can 
be used to identify that molecule.[41] 
As the corresponding band for water (OH vibrations) is sometimes too intense 
and wide for the hydrated sample it can hide or camouflage areas of the spectrum 
corresponding to important functional groups. As such, it often comes up the 
lyophilization of samples, for total removal of water, and are then plotted the infrared 
spectrumsof lyophilized samples that was what happened in this work. Thus 100 µl of 
the functionalized SLNs as well as reference SLNs (without functionalization) were 
lyophilized and infrared spectra plotted using a Frontier FT-IR Spectrometer from 
PerkinElmer (Santa Clara, California, USA). 
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Figure 10●Molecular Structure of  fluorescein 
biotin. 
Fluorometric assay 
In addition to the infrared spectra, fluorometric assays were also performed to 
confirm the functionalization of the nanoparticles using a fluorescein biotin (in detail in 
figure 11) that can be used to quantify 
available biotin-binding sites through the 
strong quenching associated when this 
molecule binds to avidin. The fluorometric 
assays were performed in a Jasco FP-6500 
spectrofluorometer (Easton, MD, USA). 
When biotinylated fluorescein binds 
to the avidin, this decreases the fluorescence due to quenching phenomenon. Thus, in 
the case of NPs conjugated with ApoE, the fluorescence signal must be greater 
because the avidin sites are occupied by ApoE and the fluorophore cannot bind, 
remaining free in solution. In the case of non-conjugation of ApoE to avidin-NPs, the 
fluorescence signal decreases due to the binding of biotin to avidin available in NPs. 
Thus, a solution with probe was prepared at200 mg/ml. The samples diluted in 
PBS (1:400) were incubated with biotinylated fluorescein during 30 minutes and then 
centrifuged in tubes with 100 nm filter at 4300 rpm until all the supernatant is 
collected (approximately 5 minutes). Samples supernatants were then gathered and its 
fluorescence read. The fluorescence (emission at λem=518 nm) of thefree 
fluoresceinbiotinwas detected by exciting the probe at a wavelength ofλex=496 nm 
(previously determined by tracing the excitation and emission spectra of this probe). 
Statistical analysis  
Statistical analyses were performed using SPSS software (v 18.0; IBM, Armonk, 
NY, USA). The measurements were repeated at least three times and data were 
expressed as mean ± SD. Data were analyzed using one-way analysis of variance (one-
way ANOVA), followed by Bonferroni, Tukey and Dunnett post-hoc tests. A p value of 
0.05 was considered statistically significant. 
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Table I– Times of Ultra-Turrax and sonication, sonication intensity and composition of the 
surfactant (polysorbate 80) tested for different SLNs formulations. 
Results and Discussion 
 
Optimizing parameters of SLNs production method  
The experimental part of this dissertation was initiated with the optimization of 
SLNs production at a level of size, not forgetting the stability over time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ultra-Turrax 
(s) 
Sonication Polysorbate 
80(%) 
 
Time(min) Amplitude (%) 
SLN 1 30 5 80 3 
SLN 2 120 5 80 3 
SLN 3 120 15 80 3 
SLN 4 120 15 90 3 
SLN 5 120 30 80 3 
SLN 6 120 60 80 3 
SLN 7 120 90 80 3 
SLN 8 120 30 90 3 
SLN 9 120 60 90 3 
SLN 10 120 15 100 3 
SLN 11 120 30 100 3 
SLN 12 120 15 60 3 
SLN 13 120 5 60 3 
SLN 14 120 30 60 3 
SLN 15 120 5 50 3 
SLN 16 120 15 50 3 
SLN 17 120 30 50 3 
SLN 18 120 5 60 5 
SLN 19 120 5 50 5 
SLN 20 120 5 70 3 
SLN 21 120 5 60 2 
SLN 22 120 10 50 3 
SLN 23 120 10 60 3 
SLN 24 120 5 50 4 
SLN 25 120 5 55 3 
SLN 26 120 5 50 2 
SLN 27 60 5 50 2 
SLN 28 60 5 60 2 
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Table II–Size and PI for the different SLNs synthesized with 
different conditions. 
The objective was to develop SLNs with an average size less than 200 nm to 
easily reach and cross their target (BBB).For this purpose, it has been tested some 
parameters of the high shear homogenization and ultrasound methodtechnique in the 
SLN production as well as different compositions of the lipid nanoparticles (proportion 
of solid lipid and surfactant). Several combinations of time of stirring, time of 
sonication and sonication intensity combined with different compositions were tested 
to establish the best conditions for 
the production of formulations 
(Table I). 
As the goal in this step was 
to optimize the size of nanoparticles 
we have performed assays to 
measure the size of particles 
synthesized and the PI that gives us 
an idea of the heterogeneity of the 
sample.The results of this pre 
evaluation can be seen in Table II. A 
compromise between the adequate 
size, a low PI and also a good 
stability of the samples had to be 
considered for the final choice of the 
parameters to be used for SLNs 
synthesis.  
In an attempt to preliminarily 
evaluate the temporal stability of 
the samples over time the SLNs with 
different compositions and 
preparation parameters were 
assessed approximately 3 weeks 
after they have been synthesized. 
Thus, all formulations were characterized visually particularly in terms of milky 
 
Size(nm) Polydispersityindex 
 SLN 1 158,0 0,098 
SLN 2 195,0 0,005 
SLN 3 176,0 0,219 
SLN 4 168,0 0,108 
SLN 5 144,4 0,110 
SLN 6 150,3 0,170 
SLN 7 146,4 0,144 
SLN 8 193,4 0,145 
SLN 9 203,6 0,157 
SLN 10 168,3 0,159 
SLN 11 179,2 0,141 
SLN 12 151,8 0,139 
SLN 13 125,0 0,176 
SLN 14 135,0 0,088 
SLN 15 99,0 0,314 
SLN 16 138,5 0,124 
SLN 17 142,9 0,100 
SLN 18 129,1 0,178 
SLN 19 144,3 0,164 
SLN 20 155,3 0,137 
SLN 21 116,5 0,145 
SLN 22 101,2 0,294 
SLN 23 137,6 0,080 
SLN 24 117,0 0,211 
SLN 25 87,4 0,309 
SLN 26 80,8 0,323 
SLN 27 145,1 0,103 
SLN 28 103,3 0,146 
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appearance, presence of granules, air bubbles and foam, twophases and deposit 
formation (see table AI in annex).  
Taking all this considerations into account, the final parameters chosen were 
120 seconds of stirring in Ultra-Turrax, followed by 15 minutes of 80% intensity 
sonication, and a percentage of 3% of polysorbate 80 corresponding to the SLN 3. 
Characterization of non-functionalized SLNs  
Before the functionalization of SLNs, the formulations with different 
concentrations of resveratrol (0, 2, 5, 10, and 15 mg) werecharacterized according to 
their morphology, entrapment efficiency, average size, zeta potential and resveratrol 
release pattern. 
Morphology 
The morphology of the lipid nanoparticles (SLN Placebo) and resveratrol-loaded 
lipid nanoparticles (SLN RSV) was observed by TEM (figure 12 and figure 13, 
respectively). The images reveal that both SLNs were almost spherical and uniform in 
shape with smooth surfaces.As can be seen in figure 11 and 12 the mean 
diameterdoes not exceed the 200 nm. It is possible to see particles in the range of 
100–200 nm or smaller and there was no visible aggregation of particles. TEM images 
revealed that these formulations producedtwo populations of nanoparticles, one most 
abundant with a smaller diameter, and other, less pronounced, with a larger 
Figure 11 ● TEM image of SLN Placebo. 
0.5 µm 
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size.Undoubtedly, for both formulations (SLN Placebo and SLN RSV) the most frequent 
population of particles has a diameter lower than150nm. 
Furthermore, the incorporation of resveratrol did not seem to cause 
morphological changes or crystal formation.Resveratrol-loaded lipid nanoparticles 
have a shape similar to placebo ones and the diameter seems to be in the same scale. 
 
Resveratrol EE 
 Lipid nanoparticles are known to be suitable systems for drug incorporation 
that can prevent degradation and give protection to drug. The lipophilic nature of 
resveratrol that have a octanol/water partition coefficient (log P) of3.1 (predicted by 
the PubChem database) suggested its preferential partition into the lipid nanoparticles 
matrix instead of remaining in the aqueous mediawhat makes this type of 
nanoparticles quite advantageous for the incorporation of resveratrol. 
The EE of each SLN formulation with a different resveratrol concentration is 
shown in Table III. The percentage of encapsulation of SLNs with resveratrol was found 
to be satisfactorily high, with an average EE of about 80%. With the increasing 
concentration of resveratrol used the entrapment efficiency of the drug decreases as 
would be expected, however the statistical analysis showed that the resveratrol con-
centration used, in the preparation of the formulations had no significant effect on the 
percentage of entrapment obtained (P > 0.05).  
Figure 12 ● TEM image of SLN RSV. 
0.5 µm 
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Table III– Characterization of resveratrol-loaded SLNs. All values represent the mean ± SD (n=3). No statistically significant 
differences where observed between any of the nanoparticle formulations (p > 0.05). 
In summary, this type of solid lipid nanoparticles prepared with the optimized 
parameterscould be considered suitable systems for resveratrol incorporationbecause 
it has high rates of encapsulation. 
Particle size measurements 
The mean particle sizes of the SLNs measured by DLS are presented in Table III. 
Both unloaded and resveratrol-loaded nanoparticles showed a homogenous size 
distribution with a mean diameter of about 150 nm and no statistically significant 
differences were observed (P > 0.05)between them, suggesting that resveratrol 
incorporation does not influence the nanoparticles size. Furthermore, it is important to 
note that the size of nanoparticles determined by DLS is carried out in aqueous state 
meaning that the lipid nanospheres are highly hydrated and because of that the 
diameters detected by this technique are usually larger than the non-hydrated 
diameters. Therefore the particles size obtained by DLS is in agreement with the 
results obtained by TEM, with slightly smaller sizes observed using the microscopic 
technique. TEM gives us an overview of all populations of nanoparticles as well as their 
diameters while the DLS, give us an average size of all sub populations. 
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Meanwhile, PI values obtained were lower than 0.2 for all nanoformulations 
(Table III), suggesting that thenanoparticles were in a state of acceptable 
monodispersity distribution, with low variability and no aggregation. In fact, this type 
of distribution is usual in lipid nanoparticles made using the high shear 
homogenization and ultrasound method and is very difficult to achieve a unimodal 
distribution of sizes.[2] 
The mean diameters confirmed that the kind of lipid nanoparticles produced 
are submicron colloidal carriers, suitable for reach and cross the BBBas intended, 
because they have a reduced diameter with lower PI, showing that the optimization of 
the nanoparticles was successful. 
Zeta potentialmeasurements 
As previously described the magnitude of the zeta potential gives an indication 
of the potential stability ofthe colloidal system.If all the particles have a very negative 
or very positive charge they will repel each other and therefore the dispersion will 
have a good stability. If particles have a low zeta potential, there will be agglomeration 
and instability in the dispersion.In general, particles can be considered stably dispersed 
when the absolute value of the zeta potential is above 30 mV due to the electric repul-
sion between the particles, while potentials between 5 mV and 15 mV result in limited 
flocculation and potentials between 0 mV and 5 mV yield a maximum flocculation.[2] 
As can be seen in table III all nanoformulations presented a negative average 
zeta potential of around -12 mV regardless of resveratrol incorporation, suggesting 
that resveratrol did not significantly change the zeta potential of the lipid 
nanoparticles (P >0.05).Hence, the lipid nanoparticles that were developed in the 
present work may be considered physicallystable due to the electrostatic repulsion 
conferred by the chemical nature of the lipid matrix, the polysorbate surfactant used, 
and possibly the adsorption of negatively charged ions onto the surface of the lipid 
nanoparticles. However is necessary to do a stability study to comprove the stability of 
this formulation over the time, since there may be some flocculation and aggregation 
once the zeta potential is not very high. 
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Figure 13 ● In vitro resveratrol release profiles from resveratrol-loaded lipid nananoparticles with 
different concentrations of resveratrol, in SBF, simulating the blood stream conditions, at body 
temperature (37°C).All data represent the mean ± SD (n = 3). No statistically significant differences 
were observed over the time for any resveratrol concentration (P>0.05). 
 
Release studies 
  
 
 
 
 
 
 
 
In vitro resveratrol release studies were performed in SBF (simulated body 
fluid) to simulate the blood stream conditions. In lipid nanoparticles the release of the 
drug loading is performed by diffusion of the drug from the inside of the particle or by 
degradation of the lipid matrix of SLNs. 
Resveratrol is predominantly lipophilic, hence its tendency to localize at the 
core of the nanoparticle, but it also has three hydroxyl groups, which tend to localize 
at the interface near the shell, favoring the initial burst release within 5 hours that is 
shownin the figure 13 by the rapid release of resveratrol during the first 5 hours of 
assay. 
 
In general, the statistical analysis showed that the resveratrol concentration 
used in the preparation of the formulations had no significant effect on the percentage 
of release (P > 0.05).SLNs had a resveratrol release almost residual for several hours 
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achieving a maximum release of 25%. This allows us to conclude that only residual 
amounts of resveratrol are released until SLNs reach their target, getting a large part of 
the encapsulated compound before crossing the BBB. In addition28 hours after, the 
resveratrol release appears to reach a stationary phase providing possiblya more 
controlled and prolonged release of the encapsulated compound remaining. 
Moreover, the degradation of the lipid matrix occurs mainly by lipases while 
only a small part is degraded by non-enzymatic hydrolytic processes. Another enzyme 
responsible for SLN degradation is the endogenous alcohol dehydrogenase. The tween 
80 is a PEG-containing surfactants that provides a sterically protective layer of varying 
thickness depending on the structure and number of PEG units. The protective layer 
more or less hinders the lipid from the enzyme attack obstructing the anchorage of the 
lipase/colipase system. The lipid used in the synthesis of nanoparticles also influence 
the degradation rate, a higher degradation rate was observed for glyceride based SLN 
than for wax based SLN (e.g. cetylpalmitate). In fact waxes are not optimal substrates 
for lipase/colipase that preferentially metabolize glycerides. [31] For all this reasons it is 
expectable that SLNs in the bloodstream does not release resveratrol prematurely.  
 
Stability study 
 In order to evaluate the stability over time, each formulation was evaluated for 
average size, zeta potential and entrapment efficiency over 2 months (in the first 
week, after one month of storage and after two months of storage).  
The physical stability of the lipid nanoparticles was evaluated firstlyby 
examining changes of mean particle sizes during storage conditions that is shown in 
figure 14. For some formulations there are statistically significant differences (P < 0.05) 
particularly when comparing the average diameter after 2 months of storage with the 
initial average diameter, after the synthesis. For most of the formulations the average 
diameter increased after 2 months of storage. However this increase is slightly 
notorious what refutes the possibility of aggregation and agglomeration. Thus no 
aggregation is predicted for these formulations despite the slight increase in the 
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Figure 14 ● Effect of time of storage (at 10°C) on particle size forSLNs at different concentrations of 
resveratrol.Notes: Z-average after 1 week ( ), 1 month (  ), 2 months (  ), and PI ( ). All data 
represent the mean ± SD (n = 3). (*) denotes statistically significant differences (P < 0.05). 
 
sizewhich is not worrying from my point of view since the average diameter does not 
exceed 200 nm in most cases.  
  
 
 
The physical stability of the lipid nanoparticles was also verified periodically by 
analyzing the variation of the zeta potential (figure 15). Zeta potential is a key factor in 
the evaluation of the stability of colloidal dispersions, since it is a function of the 
surface charge that gives the magnitude of the electrostatic repulsive interactions 
between particles. It is already shown earlier that the SLNs synthesized have a zeta 
potential of around-12mV which could lead to some aggregation between particles. 
However with these results we conclude that the stability over time of SLNs 
synthesized is not compromised sinceno tendency for zeta potential to change was 
found during storage conditions for SLNs with and without resveratrol (P > 0.05). 
* 
* * * 
* 
* 
* 
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Figure 15 ● Effect of time of storage (at 10°C) on zeta potentialforSLNs at different concentrations 
of resveratrol.Notes: Z-average after 1 week ( ), 1 month (  ) and 2 months (  ). All data 
represent the mean ± SD (n = 3). No statistically significant differences were observed over the 
time for any resveratrol concentration (P> 0.05). 
Finally the physical stability of the lipid nanoparticles was also verified in terms 
of entrapment efficiency of resveratrol over the time.SLNs are characterized by having 
a highly organized matrix that tends to form perfect crystals over time which can 
eventually lead to an expulsion of the drug during the storage period. This is the main 
disadvantage of solid lipid nanoparticles hence the high interest in evaluating the 
quantity of resveratrol encapsulated over the time. Nevertheless as can be seen in 
figure 16 the entrapment efficiency hardly changed during the two months, with no 
significant differences between the amount of resveratrol encapsulated after synthesis 
and the amount of encapsulated resveratrol past two months. This suggests that SLNs 
retain the encapsulated compound over time precluding the possibility of expulsion of 
the drug, showing once again the stability of these formulations.  
In general, this long-term stability study demonstrates thatthe optimization of 
SLNs done in this study resulted ina dynamic stable system capable of being used as 
controlled-release schemes for brain targeted resveratroldelivery, having an average 
size well below 200 nm. So the next step was the functionalization of the nanoparticles 
with ApoE to brain targeting. 
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Figure 16 ● Effect of time of storage (at 10°C) on resveratrol entrapment efficiency for SLNs at different 
concentrations of resveratrol.Notes: Z-average after 1 week ( ), 1 month (  ) and 2 months (  ). All 
data represent the mean ± SD (n = 3).  No statistically significant differences were observed over the 
time for any resveratrol concentration (P > 0.05). 
 
 
 
 
 
 
 
 
SLNs Functionalized with ApoE  
As already referred,the functionalization of solid lipid nanoparticles with ApoE 
was performed by two strategies:(i) using a phospholipid (DSPE-PEG-NH2) to which 
avidin is added experimentally; and (ii) using palmitate with a terminal NHS that can 
also react with avidin. It was subsequently performed the characterization of each 
separately using the same parameters analyzed for the SLNs without functionalization: 
morphology, average size, PI, zeta potential and EE. The successful of functionalization 
was also confirmed by FTIR and fluorometric assays. 
Strategy I: SLNs with DSPE-PEG-ApoE 
 In this case the particles are prepared incorporating DSPE-PEG-NH2 in its 
composition. Subsequently, the avidin is conjugated to the nanoparticles by peptide 
bond between the amine terminal group of DSPE and the carboxyl group of avidin 
forming thereby nanoparticles conjugated with avidin. Finally the particles are added 
to previously biotinylated ApoE. 
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 As in SLNs without functionalization, 
the functionalized SLNs morphology was 
analyzed by TEM. In figure 17 and 18 are 
shown the images recorded in the TEM 
concerning the ApoE functionalized SLNs with 
(SLN-DSPE-ApoE RSV) and without (SLN-DSPE-
ApoE Placebo) resveratrol. 
As expected the SLNs functionalized 
have a spherical shape perfectly defined and is not visible aggregation and 
agglomeration of nanoparticles. Once again these formulations produce two 
populations of nanoparticles, one most abundant with a smaller diameter, and other, 
less pronounced, with a slightly large size.It is noted that, according to TEM images, 
the most abundant population has an average diameter less than 200 nm 
demonstrating again that the initial step of optimizing the size of the particles was 
successful. 
In this case, resveratrol did not seem to cause morphological changes or crystal 
formation once resveratrol-loaded lipid 
nanoparticles have a shape similar to placebo 
nanoparticles and the diameter seems to be 
in the same scale. 
The results of average size, PI, zeta 
potential and entrapment efficiency are 
compiled in table IV. This table shows the 
characterization of SLNs without 
functionalization (to comparison), SLNs only with DSPE (SLN-DSPE-NH2), SLNs with 
avidin linked to DSPE (SLN-DSPE-Avidin) and SLNs with ApoE that is linked to 
avidin(SLN-DSPE-ApoE). 
As can be seen in table IV the average size and PIdid not change significantly 
with the nanoparticle functionalization using DSPE. The zeta potential remained 
Figure 17 ● TEM image of SLN-DSPE-ApoE 
Placebo. 
Figure 18 ● TEM images of SLN-DSPE-ApoE RSV. 
0.5 µm 
0.5 µm 
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Table IV– Characterization of SLNs with ApoE using DSPE. All values represent the mean ± SD (n=3). Results of 
SLNs without drug were analyzed and compared with SLN Placebo (no functionalization), and the results of SLNs 
with resveratrol were compared to SLN RSV (no functionalization). (*) denotes statistically significant 
differences (P < 0.05). 
 
unchanged in the functionalized particles (SLN-DSPE-ApoE), maintaining its potential in 
the order of -12 mV what is optimal to not compromise the stability of the particles. 
Concerning SLNsonly with DSPE-PEG-NH2, the phospholipid has a terminal amine which 
at a pH of 7.4 is ionized, NH3
+, giving positive charge to the nanoparticles. 
  
In terms of entrapment efficiency the functionalization did not change the high 
rate of encapsulation of resveratrol already obtained for this type of nanoparticles 
since no significant differences were recorded at the level of entrapment efficiency 
between particles with and without functionalization (p > 0.05).  
 The nanoparticles have an average size less than 170 nm, with a good 
polydispersity (< 0.2), a zeta potential reasonably high to not allow clustering (~ -12 
mV) and resveratrol entrapment efficiencyvery high (~ 90%). Thus we can conclude 
that the functionalization of the SLNs with ApoE using DSPE-PEG-NH2 is a very 
promising technique that originates nanoparticles theoretically capable of reaching the 
BBB and go through it to reach the brain where resveratrol may exert its beneficial 
therapeutic effects.  
 
Resveratrol Loaded Lipid Nanoparticles for Brain Targeted Delivery 2013 
 
55  
 
Figure 20 ● TEM images of SLN-Palmitate-ApoE 
RSV. 
Strategy II: SLNs with Palmitate-ApoE 
 In this case the process started with an avidin palmitoylation resulting in the 
formation of avidin palmitate which is then added to the lipid phase during the 
synthesis of SLNs. ApoE previously biotinylated is thereafter linked to the SLNs by 
avidin-biotin binding. Then the nanoparticles were characterized regarding 
morphology, average size, zeta potential and entrapment efficiency. 
 As for the other formulations, the SLN-
Palmitate-ApoE morphology was analyzed by 
TEM. In figure 19 and 20 are shown the images 
recorded in the TEM without and with 
resveratrol, respectively. 
As can be seen in figure 19 SLNs 
functionalized with ApoE using palmitate 
appears to be spherical with smooth surfaces in 
the case of SLNs placebo. Resveratrol-loaded 
ones (figure 20) are also spherical but seem to havea wrinkled surface maybe because 
the resveratrol content inside the nanoparticles. In general,the diameter of these 
functionalized nanosystems and placebo 
nanoparticles seems to be in the same scale. 
However, SLNs functionalized using palmitate 
seem to have an average size superior to SLNs 
functionalized using DSPE, but we can only 
draw assertive conclusions after analyze the 
average hydrodynamic size of the particles 
obtained by DLS. 
 
The results of average size, PI, zeta potential and entrapment efficiency for this 
type of functionalization are summarizedin table V. This table shows the 
characterization of SLNs without functionalization (to comparison), SLNs with avidin 
Figure 19 ● TEM images of SLN-Palmitate-
ApoE Placebo. 
0.5 µm 
0.5 µm 
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Table V– Characterization of SLNs with ApoE using palmitate. All values represent the mean ± SD (n=3). Results 
of SLNs without drug were analyzed and compared with SLN Placebo (no functionalization), and the results of 
SLNs with resveratrol were compared to SLN RSV (no functionalization). (*) denotes statistically significant 
differences (P < 0.05). 
 
palmitate(SLN-Palmitate-Avidin) and SLNs with ApoE that is linked to avidin (SLN-
Palmitate-ApoE). 
 In this case significant differences were observed in the average size of SLNs 
functionalized in comparison with the reference nanoparticles (without 
functionalization), as would be expected by the images obtained from TEM. The 
average size round the 200 nm, but the population is more homogeneous because PI is 
lower when compared to particles without functionalization. One interesting fact is 
that resveratrol-loadedfunctionalized SLNs have a higher average size than the non-
loadedfunctionalized SLNs which is explicable by the presence of resveratrol molecule 
inside the nanoparticles.At the same time they have a lower PI suggesting almost an 
unimodal dispersion which can be quite useful. 
Regarding zeta potential the functionalization did not change this parameter, 
even thought there is a slight increase in the negative zeta potential of the NPs. There 
were no significant differences in rates of drug encapsulation suggesting that the 
functionalization and the entire protocol for the addition of ApoE to NPs do not 
promote the expulsion of the drug.  In reality with functionalization we can increase 
the entrapment efficiency to nearly 100%, however, it is very important to conduct a 
study of the stability of the NPs along time to check if the drug is not prematurely loss. 
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Figure 21 ● In vitro resveratrol release profiles from non-functionalized SLNs and  functionalized SLNs 
(SLN-DSPE-ApoE RSV and SLN-Palmitate-ApoE RSV), in SBF, simulating the blood stream conditions, at 
body temperature (37°C).All data represent the mean ± SD (n = 3). (*) denotes statistically significant 
differencesin relation to SLN RSV with no functionalization (P < 0.05). 
 
 
This nanoparticles have an average size of around 200 nm, with a very good 
polydispersity (< 0.15), a zeta potential reasonably high (~ -15 mV) to not allow 
clustering and resveratrol entrapment efficiencyvery high (~ 90%).Therebyit is possible 
to say that the functionalization of the SLNs with ApoE using the avidin palmitate can 
also be a very promising technique that can be used to resveratrol delivery to BBB. 
 
Release study with functionalized nanoparticles 
 
For both types of functionalization,the resveratrolrelease assays were 
performed to verify if the addition of ApoE affected the controlled release of the drug. 
In vitro resveratrol release studies were performed in SBF to simulate the blood stream 
conditions, as previously described. This in vitro release study is a very important tool 
which is mainly useful for quality control as well as for the prediction of in vivo kinetics. 
Theresults can be seen in figure 21. 
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Figure 22 ● Effect of time of storage (at 10°C) on particle size of ApoE functionalized SLNs. 
Notes: Z-average after 1 week ( ),1 month (  ) and PI ( ). All data represent the mean ± 
SD (n = 3). No statistically significant differences were observed over time for any 
formulation (P > 0.05). 
Analyzing the results obtained we can conclude that there were no statistically 
significant differences in drug release with the nanoparticle functionalization. 
Moreover, it has been registered a more controlled resveratrolrelease, almost linear, 
from the functionalized SLNs in both functionalization strategies. The initial burst 
release during the first 5 hours is not as pronounced as it was in non-functionalized 
SLNs. In general, the drug release is made in a more gradual way after the addition of 
ApoE. Therefore, it is possible to infer that the functionalization does not compromise 
the sustained release of resveratrol in the blood stream. 
 
Stability study of functionalized nanoparticles 
 After the characterization and the evaluation of drug release it is preponderant 
to evaluate if the stability of SLNs changed with the addition of ApoE. In this case due 
to the lack of time, the stability study for functionalized NPs could only be performed 
for 1 month. Each formulation was evaluated for average size, zeta potential and 
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Figure 23 ● Effect of time of storage (at 10°C) on zeta potentialof ApoE functionalized 
SLNs. Notes: Z-average after 1 week ( ) and 1 month (  ). All data represent the mean 
± SD (n = 3). No statistically significant differences were observed over time for any 
formulation (P > 0.05). 
entrapment efficiency in the first week and after one month of storage. 
 In figure 22 is possible to see the results of the variation in average particle size 
over time. As can be seen size does not change significantly over time indicating that 
there are no aggregation of particles (p >0.05) and that they are stable in solution after 
1 month. Therefore, the ApoE functionalization of SLNs using DSPE or palmitate, 
originate stable formulations which do not form clusters during at least the first one 
month. 
 
 
 
 
 
 
 
 
 In relation to the zeta potential the addition of ApoE to the SLNs did not 
significantly alter the charge on the surface of the particles over time. Afterone 
monthofstoragenosignificant changesin thezeta potentialofNPsfunctionalized can be 
seen in figure 23, what isfundamentalto good stabilityofNPsin solution.Finally the 
physical stability of the lipid nanoparticles was also verified in terms of entrapment 
efficiency of resveratrol over the time (figure 24). Regarding the drug encapsulation 
rate,the quantity of encapsulated drug does not change significantly after one month 
of storage for SLNs functionalized with ApoE remaining above 90%. 
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Figure 24 ● Effect of time of storage (at 10°C) on resveratrol entrapment efficiency of 
ApoE functionalized SLNs. Notes: Z-average after 1 week ( ) and 1 month (  ). All data 
represent the mean ± SD (n = 3).  No statistically significant differences were observed 
(P > 0.05). 
Figure 25 ● Infrared spectrum obtained by FTIR for SLNs with no functionalization (SLN Placebo and SLN RSV); SLNs 
with avidin palmitate (SLN-Palmitate-Avidin Placebo and RSV) and avidin palmitate as a reference to compare with 
the functionalized samples. 
 
 
 
 
 
 
 
 
In short, this long-term stability study demonstrates that the functionalization 
of SLNs with ApoE resulted in a dynamic stable system capable of being used as 
controlled-release schemes for targeting brain delivery of resveratrol by crossing the 
BBB via LDL receptor with average sizes in the order of 150 to 200 nm. No changes in 
mean particle sizes and zeta potential during storage conditions for 1 month have 
been reported. The entrapment efficiency remained very good with percentages of 
encapsulation over 90% indicating that there is no loss ofresveratrol during storage. 
FTIR 
To prove that the functionalization was successful and that the ApoEis in fact 
linked to SLNswe had collected infra-red spectra for each lyophilized sample using 
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Figure 26 ● Infrared spectrum obtained by FTIR for SLNs with no functionalization (SLN Placebo and SLN RSV); 
SLNs with ApoE (SLN-Palmitate-ApoE Placebo and RSV) and biotinylated ApoE as a reference to compare with 
the functionalized samples. 
Figure 27 ● Biotin Structure. 
FTIR. This makes possible to identify functional groups that lead to the detection and 
identification of avidin and ApoE in the formulations. A preliminary result consisted in 
demonstrate the presence of avidin in the particles for subsequent functionalization 
with ApoE. As can be seen in figure 25 there were twomain peaks that stand out and 
demonstrate the presence of avidin. Thesetwo peaks match both to the NH groups 
that exist in the peptide bonds between aminoacids that form avidin. For particles not 
functionalized there are no NH groups so their presence comproves the presence of 
avidin linked to nanoparticles. There are one peak at ~ 1550 cm-1 that corresponds to 
bending vibrations of NH and other peak at ~ 3400 cm-1 (not so evident) that 
corresponds to strech vibrations of the same group.  
 
In figures 26 and 28 it is possible toconfirmethe presence of ApoE. In both types 
of functionalization are present two quite 
evident peaks which are not present in non-
functionalized SLNs. One of them at ~ 800 cm-1 
that corresponds to C-S bondsonly present in 
biotin (see figure 28). The other peak at ~ 
1050 cm-1 represents C-N bonds that are 
greatly increased in the presence of 
biotin(although there are also in avidin). Thus it is shown the presence of ApoE in 
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Figure 29 ● Fluorometric assay using fluorescein biotin to comprove the presence of ApoE in the samples 
functionalized using palmitate. Blue lines represent formulations with ApoE and green lines represent 
formulations with only avidin (without ApoE linked).  
Figure 28  ● Infrared spectrum obtained by FTIR for SLNs with no functionalization (SLN Placebo and SLN RSV); SLNs 
with ApoE (SLN-DSPE-ApoE Placebo and RSV) and biotinylated ApoE as a reference to compare with the 
functionalized samples. 
 
functionalized NPs once ApoE is biotinylated prior to addition to the particles (with the 
excess of biotin that did not bind removed by dialysis) and the presence of biotin is 
quite evident from the results of FTIR. 
 
Fluorometric assay 
In addition to the infrared spectra, fluorometric assays were also performed to 
confirm the functionalization of the nanoparticles using a fluorescein biotin. This probe 
wasused to quantify available biotin-binding sites on avidin. As already mentioned in 
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Figure 30 ● Fluorometric assay using fluorescein biotin to comprove the presence of ApoE in the samples 
functionalized using DSPE. Blue lines represent formulations with ApoE and green lines represent formulations 
with only avidin (without ApoE linked).  
materials and methods section there is a strong quenching phenomenon (the 
fluorescence intensity decreases) when the fluoresceinbinds to the free avidin sites on 
the surface of the NPs. So, if the functionalization is successful there will be little or no 
binding sites for the probe which will result in a maximum fluorescence of the 
fluorescein that is mostly in solution and thus expresses its fluorescence. Therefore the 
probewas incubated with the samples functionalized with ApoE and samples with 
avidin alone (without binding ApoE) for comparing the fluorescence obtained. Of 
course, when we have formulations only with avidin, there will be many sites for 
binding of fluorescein biotin resulting in a very sharp decrease in probe 
fluorescence.Figure 29 and 30 illustrates the results of fluorometric assays for SLNs 
functionalized with ApoE using palmitate and DSPE, respectively. As can be seen,there 
is a more pronounced fluorescence for SLNs with ApoE due to the lack of binding sites 
to the probe that are occupied by the presence of biotinylated ApoE. In both cases, 
there is an increaseof fluorescence when compared SLNs only with avidin with SLNs 
with ApoE proving the presence of ApoE in the functionalized NPs. 
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Conclusion 
  
The amazing growth in recent years of CNS studyhas generated enormous 
research efforts in an attempt to develop new drugs for brain diseases. However there 
are a low number of drugs entering the market what reflects the complexity of the 
CNS, certainly in great part due to the difficulty of crossing the BBB and reach the 
brain. Essentially 100% of large drugs and >98% of small drugs do not cross the BBB. 
Here the nanotechnology can be an important tool to improve the affinity of some 
drugs to the BBB, allowing them to be able to reach and cross this barrierand reach the 
brain. 
The aim of this work is to take advantage of the neuroprotective effects of 
resveratrol. However when the compound is administered in its free form, little or no 
drug reach the brain due to its low bioavailability, low water solubility, and its chemical 
instability which causes a rapidly and extensively metabolization and excretion. 
SLN delivery can be a promising way to administer drugs into the brain possibly 
overcoming the problems of solubility, permeability and toxicity associated with the 
administration of the free drug. It has been previously described that lipid NPs 
represent, in fact, promising carriers since their prevalence over other formulations in 
terms of toxicity, high stability, production feasibility and scalability. 
In this study we developed a system capable of transport resveratrol, drive it to 
the brain facilitating its passage through the BBB, and allowing its sustained release 
over time by adding ApoE to SLN formulations. ApoE-functionalized SLNs may mimic 
lipoprotein particles that are endocytosed into the BBB endothelium and transcytosed 
through the BBB endothelium to the brain. 
It was possible to successfully accomplish all the goals initially proposed. The 
optimization of SLNs done in this study resulted in dynamic stable systems capable of 
being used as controlled-release schemes for targeting brain delivery of resveratrol, 
having an average size well below 200 nm a reasonably negative zeta potential            
(~ -15mV) and high rates of encapsulation of resveratrol (over 90%). Functionalization 
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of SLNs with ApoE was clearly demonstrated through fluorometric assays and the 
infrared spectra (using FTIR) for both types of functionalization performed. The 
functionalization of the SLNs with ApoE using DSPE or palmitate is a very promising 
technique that originates nanoparticles theoretically capable of reaching the BBB and 
go through it to reach the brain where resveratrol may exert its beneficial therapeutic.  
This addition of ApoE to the formulations did not change significantly thelong-
term stability of the formulations already evaluated previously (for SLNs without 
ApoE). In fact for functionalized NPs,no changes in mean particle sizes and zeta 
potential during storage conditions for 1 month have been reported and the 
entrapment efficiency remained very good, indicating that there are no losses of 
resveratrol during storage.  
Regarding the release of resveratrol there was no statistical significant 
differences after adding ApoE to SLNs suggesting that the functionalization does not 
compromise the sustained release of the drug.  
This new approach of SLNs functionalization with ApoE had never been 
described before and it was quite successful developed.  
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Figure 31 ● Microscope image of hCMEC/D3 cell line. 
Future work 
 
Only in future it will be possible to say what type of functionalization is the best 
and the most profitable in therapeutic terms. Now it is necessary to show the 
effectiveness of each system in the improving of SLNs uptake into the brain. Therefore, 
it will of great importance to show and verify the advantages and effectiveness of 
these innovative SLNs formulations functionalized with ApoE through cellular studies in 
vitro. These studies will be done in hCMEC/D3 cell line showed in figure 31 that 
corresponds to immortalized human cerebral microvascular endothelial cells used as a 
model of human BBB.  
 
 
 
 
 
 
 
In hCMEC/D3 cell line it will be done studies of cell viability and integrityby MTT 
assay and LDH test. It will also be held permeability studies in Transwell® permeable 
supports to assess whether in fact the functionalization of nanoparticles facilitates 
their passage through BBB. In addition is necessary to check if the functionalization 
induces an increased uptake of the NPs into the cells doing internalization studies 
using fluorescence microscopy and or flow cytometry.  
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Figure A.1 ● Pictures of the SLNs synthesized during the optimization process. 
Annex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table AI ● Visual characterization of the SLNs synthesized during the optimization process 
 
SLN 1 Yes Very few Yes - A very small stage in the background translucid Very few No Small granules It is possible to observe some sediment in the formulation tube wall 
SLN 2 Yes Very few and small No Very few No No Looks good, very milky, with almost imperceptible granules
SLN 3 Yes No No Very few No No It is possible to observe some sediment in the tube wall of formulation, but the solution is apparently uniform
SLN 4 Yes No No Very few No No É possível observar vários sedimentos na parede do tubo de formulação
SLN 5 Yes Very few No Very few No No It is possible to observe various sediment in the formulation tube wall
SLN 6 A little bit Some No Few No No Some sediment cling to the wall and does not flow after shaking
SLN 7 A little bit Some No Yes No or very few No (small sediments) After shaking several small air bubbles and sediment does not flow and remain on the wall
SLN 8 A little bit Yes (some big) No Very few No No By shaking various sediments and large granules not trickle down and remain on the wall
SLN 9 A little bit Yes No Yes No Yes (big) It can be seen that large granules remain in the formulation tube wall even after agitation
SLN 10 Yes Yes No No No No It is possible to observe various sediment in the tube wall of formulation
SLN 11 Yes Some No Yes Very few No There are several sediment in the tube wall with irregular sizes
SLN 12 Yes Yes No Yes No No Is possible to see several large sediment in the formulation tube wall
SLN 13 No Yes Yes -A phase slightly translucent and other opaque and white in equal proportions Yes Yes No Some sediment cling to the wall and does not flow after shaking
SLN 14 Yes No No No No No Excellent aspect
SLN 15 Little No Yes - A huge translucid phase and a thin film on top opaque white Yes Yes No Almost solid layer on top phase
SLN 16 A little bit No Yes - A phase translucent very small on the basis and an extensive phase opaque white Few No No
SLN 17 A little bit Very few No Very few No No Some sediment cling to the wall and does not flow after shaking
SLN 18 No Yes Yes - A translucent phase and a phase opaque and white in equal proportion Very few No Yes (sediments) The granules remain on the wall after unrest
SLN 19 Very little Yes Yes - A phase translucid (small) and a phase opaque white (large) No No Yes (sediments) Some sediment cling to the wall and does not flow after shaking
SLN 20 A little bit No No Few No No Some sediment cling to the wall and does not flow after shaking
SLN 21 No Yes Yes - A phase translucid and other opaque white in equal proportion Some No Yes (sediments) This mixture does not appears homogeneous
SLN 22 Very little No Yes - A translucent phase and a minor white phase quite foamy Yes Yes (a lot) Foam It is possible to observe various sediment in the formulation tube
SLN 23 A little bit Yes Yes - A huge white opaque phase and a translucid phase much smaller Yes Few No There is a huge lipid aggregate on top of formulation
SLN 24 No Yes
Yes - A phase almost translucent, which represents about 2/3 of the formulation, and a with opaque 
phase without foam
Some Yes Yes (sediments) Various sediments are visible on the wall that does not flow after shaking
SLN 25 No No Yes - A large and tranlucent phase and a white and opaque phase much smaller with bubbles Yes Yes No Air bubbles remain in the walls without sagging after shaking
SLN 26 Little No Yes - Phases of equal size, one quite opaque and white and olther translucid Yes No No Plenty of liquid
SLN 27 Little Some No Yes No Yes Curdled milk appearance, moves as an entire block
SLN 28 No Yes Yes - A large white and more solid phase and a translucid phase Yes Yes No It is possible to observe various sediment in the formulation tube wall
Foam Deposit Formation OthersMilk Appearance Granules 2 Phases Air bubbles
